Spirocyclic EPO Inhibitors for Renal Cell Carcinoma and Polycythemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal cell carcinoma (RCC) and polycythemia, mediated by elevated erythropoietin (EPO) levels, are inadequate, and there is a need for an effective EPO inhibitor to manage these conditions.
Innovation Solution
Development of a class of spirocyclic compounds that exhibit excellent chemical stability and significant EPO-inhibiting activity, capable of reducing EPO levels in various biochemical, biological, or cellular assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (phlebotomy, cytoreductive therapies, radioactive phosphorus, busulfan, JAK inhibitors) are used to manage elevated EPO levels, then EPO-related conditions can be treated, but treatment effectiveness is inadequate and side effects occur
Solution Approach 1:
The patent develops novel spirocyclic compounds with specific molecular structures (formula I) that represent a fundamental change in the therapeutic parameter approach. These compounds target EPO production at the molecular level, offering a more precise and effective mechanism compared to conventional treatments, thereby improving reliability while potentially reducing harmful side effects through targeted action
Solution Approach 2:
The invention employs complex spirocyclic compound structures comprising multiple fused rings and specific substituent patterns (R1-R7 groups). This composite molecular architecture enables enhanced binding affinity and selectivity for EPO-related targets, achieving superior treatment effectiveness compared to simpler conventional therapies while maintaining favorable safety profiles
2Reliability
If long-term phlebotomy and cytoreductive therapies are administered, then EPO levels can be managed, but treatment duration becomes prolonged and quality of life deteriorates
Solution Approach 1:
The spirocyclic compounds act by preliminarily blocking EPO production at its source through inhibition of EPO-related targets. This preventive mechanism addresses the root cause before polycythemia fully develops, potentially reducing the need for long-term repetitive interventions and improving quality of life while maintaining reliable EPO level control
3Reliability
If intravenous radioactive phosphorus or busulfan is used, then EPO production can be suppressed, but chemical stability and safety concerns arise
Solution Approach 1:
The patent describes small molecule spirocyclic compounds that can be administered orally or parenterally and exert their effect through transient binding to EPO-related targets. These short-acting molecular entities are metabolized and eliminated naturally, avoiding the accumulation and long-term stability concerns associated with radioactive isotopes, while achieving reliable EPO production suppression
Data Source
AI summary
The present application relates to a spiro compound and use thereof in the field of medicine. Specifically, disclosed in the present application are a compound represented by Formula (I), an isotope-labeled compound thereof, an optical isomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a crystal form or solvate form of the compound or pharmaceutically acceptable salt thereof.